KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxlinear (MXL) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Maxlinear (MXL) over the last 17 years, with Q4 2025 value amounting to $7.9 million.

  • Maxlinear's Change in Accured Expenses fell 3143.31% to $7.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $34.8 million, marking a year-over-year increase of 86082.29%. This contributed to the annual value of $34.8 million for FY2025, which is 86082.29% up from last year.
  • Per Maxlinear's latest filing, its Change in Accured Expenses stood at $7.9 million for Q4 2025, which was down 3143.31% from -$2.2 million recorded in Q3 2025.
  • In the past 5 years, Maxlinear's Change in Accured Expenses registered a high of $37.3 million during Q2 2021, and its lowest value of -$34.5 million during Q2 2023.
  • For the 5-year period, Maxlinear's Change in Accured Expenses averaged around $5.0 million, with its median value being $8.3 million (2025).
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first surged by 74770.25% in 2021, then crashed by 103598.36% in 2022.
  • Quarter analysis of 5 years shows Maxlinear's Change in Accured Expenses stood at -$1.5 million in 2021, then crashed by 1035.98% to -$16.6 million in 2022, then soared by 30.53% to -$11.5 million in 2023, then surged by 199.64% to $11.5 million in 2024, then crashed by 31.43% to $7.9 million in 2025.
  • Its Change in Accured Expenses stands at $7.9 million for Q4 2025, versus -$2.2 million for Q3 2025 and $20.4 million for Q2 2025.